Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2020 Jan 24;69(3):493. doi: 10.1007/s00262-020-02489-9

Retraction Note to: Bio‑HMGB1 from breast cancer contributes to M‑MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC‑like cells

Zhaoliang Su 1,2, Ping Ni 2, Peng She 2, Yueqin Liu 1, Seidu A Richard 2, Wenlin Xu 1, Haitao Zhu 3, Jia Wang 1,2,
PMCID: PMC11027803  PMID: 31980912

Retraction Note: Cancer Immunol Immunother (2017) 66:391–401 10.1007/s00262-016-1942-2

The Editor-in-Chief has retracted this article [1] because a number of the images in Fig. 4a and c, appear to have been duplicated then either rotated, cropped or stretched to make them appear to be different tumors. The Editor-in-Chief no longer has confidence in the results and conclusions presented in this article. Jia Wang agrees with this retraction. Seidu A. Richard does not agree with this retraction. Zhaoliang Su, Ping Ni, Peng She, Yueqin Liu, Wenlin Xu and Haitao Zhu have not responded to correspondence about this retraction.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Su Z, Ni P, She P, Liu Y, Richard SA, Xu W, Zhu H, Wang J. Bio-HMGB1 from breast cancer contributes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells. Cancer Immunol Immunother. 2017;66(3):391–401. doi: 10.1007/s00262-016-1942-2. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES